Ameluz (Aminolevulinic Acid HCl) Patent Expiration, LOE Window & CMS Spending
Ameluz (Aminolevulinic Acid HCl) by Biofrontera: FDA Orange Book LOE 2043-12-08, 0 AB generics, $305K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Biofrontera |
| FDA Application & Pathway | N208081 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2043-12-08 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $305K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $305K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |